Fulcrum Therapeutics, Inc. (FULC) stock
FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.77+0.09 (+2.45%)
Close on Nov 13, 2026Market cap $287.64MP/E –Yield –
Fulcrum Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Fulcrum Therapeutics's operating margin for the twelve months ending Dec 31, 2024 was -27.4%. For fiscal 2024 it was -27.4%, against -3945.2% the year before. The highest annual figure on record is -27.4% in fiscal 2024.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -27.4% | +3917.9 |
| FY2023 | Dec 31, 2023 | -3945.2% | −2170.4 |
| FY2022 | Dec 31, 2022 | -1774.9% | −1351.9 |
| FY2021 | Dec 31, 2021 | -423.0% | +388.7 |
| FY2020 | Dec 31, 2020 | -811.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2024 | Jun 30, 2024 | 65.6% | +9536.8 |
| Q4 FY2023 | Dec 31, 2023 | -3213.8% | +869.9 |
| Q3 FY2023 | Sep 30, 2023 | -3615.3% | −1556.5 |
| Q2 FY2023 | Jun 30, 2023 | -3101.4% | −1282.3 |
| Q1 FY2023 | Mar 31, 2023 | -9471.2% | −8468.2 |
| Q4 FY2022 | Dec 31, 2022 | -4083.6% | −3876.3 |
| Q3 FY2022 | Sep 30, 2022 | -2058.7% | −1637.9 |
| Q2 FY2022 | Jun 30, 2022 | -1819.1% | −1369.8 |
| Q1 FY2022 | Mar 31, 2022 | -1003.0% | −647.1 |
| Q4 FY2021 | Dec 31, 2021 | -207.3% | +213.7 |
| Q3 FY2021 | Sep 30, 2021 | -420.9% | +612.9 |
| Q2 FY2021 | Jun 30, 2021 | -449.3% | +346.9 |
| Q1 FY2021 | Mar 31, 2021 | -355.9% | +2150.3 |
| Q4 FY2020 | Dec 31, 2020 | -421.0% | – |
| Q3 FY2020 | Sep 30, 2020 | -1033.8% | – |
| Q2 FY2020 | Jun 30, 2020 | -796.2% | – |
| Q1 FY2020 | Mar 31, 2020 | -2506.1% | – |
See a number that looks wrong?